|
Market Closed -
NYSE
04:00:03 2026-11-02 pm EST
|
5-day change | 1st Jan Change | ||
| 186.58 USD | -0.04% |
|
+8.84% | +102.96% |
| Nov. 02 | AstraZeneca PLC : UBS reiterates its Buy rating | ZD |
| Nov. 02 | Hutchmed China hails Orpathys acceptance for review in Japan and EU | AN |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 288,452 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | 0.22% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 309,671 | 302,450 | 293,187 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -0.49% | -2.33% | -3.06% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 24.2x | 20.7x | 18.4x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 5.3x | 4.63x | 3.98x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.4x | 1.2x | 1.5x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.56x | 4.29x | 4.04x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.9x | 4.5x | 4.11x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 13.8x | 12.4x | 10.9x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 14.6x | 13x | 11.5x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 31x | 23.5x | 19.8x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.23% | 4.26% | 5.05% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.322 | 3.535 | 3.648 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.79% | 1.9% | 1.96% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.681 | 8.986 | 10.1 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.2% | 39.3% | 36.1% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,259 | 67,265 | 71,414 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,469 | 24,378 | 26,937 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,275 | 23,218 | 25,522 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,762 | 13,695 | 15,409 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 21,218 | 13,998 | 4,735 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 185.98 | 185.98 | 185.98 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 41.42x | 14.01x | 31.06x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.35% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 97.38x | 6.07x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.87x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -40.86x | 7.45x | 46.76x | 1.94% | 212B | |
| Average | 30.40x | 7.39x | 21.67x | 2.01% | 473.55B | |
| Weighted average by Cap. | 36.41x | 8.82x | 22.82x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
